Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Change in Accured Expenses (2023 - 2025)

Zenas BioPharma has reported Change in Accured Expenses over the past 3 years, most recently at $9.8 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $9.8 million for Q4 2025, down 17.4% from a year ago — trailing twelve months through Dec 2025 was $15.1 million (down 31.78% YoY), and the annual figure for FY2025 was $15.1 million, down 31.78%.
  • Change in Accured Expenses for Q4 2025 was $9.8 million at Zenas BioPharma, up from $102000.0 in the prior quarter.
  • Over the last five years, Change in Accured Expenses for ZBIO hit a ceiling of $16.3 million in Q2 2025 and a floor of -$11.2 million in Q1 2025.
  • Median Change in Accured Expenses over the past 3 years was $3.2 million (2023), compared with a mean of $4.5 million.
  • Peak annual rise in Change in Accured Expenses hit 1781.86% in 2025, while the deepest fall reached 844.33% in 2025.
  • Zenas BioPharma's Change in Accured Expenses stood at $3.2 million in 2023, then surged by 267.0% to $11.9 million in 2024, then fell by 17.4% to $9.8 million in 2025.
  • The last three reported values for Change in Accured Expenses were $9.8 million (Q4 2025), $102000.0 (Q3 2025), and $16.3 million (Q2 2025) per Business Quant data.